Anticancer drug-loaded hydrogels as drug delivery systems for the local treatment of glioblastoma.
Among central nervous system tumors, Glioblastoma (GBM) is the most common, aggressive and neurological destructive primary brain tumor in adults. Standard care therapy for GBM consists in surgical resection of the accessible tumor (without causing neurological damage) followed by chemoradiation. However, several obstacles limit the assessment of tumor response and the delivery of cytotoxic agents at the tumor site, leading to a lack of effectiveness of conventional treatments against GBM and fatal outcome. Despite the efforts of the scientific community to increase the long-term benefits of GBM therapy, at the moment GBM remains incurable. Among the strategies that have been adopted in the last two decades to find new and efficacious therapies for the treatment of GBM, the local delivery of chemotherapeutic drugs in the tumor resection cavity emerged. In this review, our aim is to provide an overview on hydrogels loaded with anticancer drugs for the treatment of GBM recently used in preclinical and clinical studies, their advantages and major limitations for clinical translation. This review is divided in three parts: the first one describes the context of GBM and its current treatments, with a highlight on the role of local delivery in GBM treatment and the development of GBM resection murine models. Then, recent developments in the use of anticancer drug-loaded hydrogels for the treatment of GBM will be detailed. The final section will be focused on the limitations for in vivo studies, clinical translation and the clinical perspectives to the development of hydrogels.
Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Avenue Mounier, B1 73.12, 1200 Brussels, Belgium.
C
C
Bastiancich
Université catholique de Louvain, Louvain Drug Research Institute, Biomedical Magnetic Resonance Unit, Avenue Mounier, B1 73.08, 1200 Brussels, Belgium.
P
P
Danhier
Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Avenue Mounier, B1 73.12, 1200 Brussels, Belgium. Electronic address: veronique.preat@uclouvain.be.
V
V
Préat
Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Avenue Mounier, B1 73.12, 1200 Brussels, Belgium. Electronic address: fabienne.danhier@uclouvain.be.
F
F
Danhier
D000328:Adult; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016503:Drug Delivery Systems; D005909:Glioblastoma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D020100:Hydrogels; D014018:Tissue Distribution
D000970:Antineoplastic Agents; D020100:Hydrogels
Drug delivery system; Gelation; Glioblastoma; Hydrogel; Local delivery